GLYC - GlycoMimetics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

GlycoMimetics, Inc.

9708 Medical Center Drive
Rockville, MD 20850
United States
240-243-1201
http://www.glycomimetics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees50

Key Executives

NameTitlePayExercisedYear Born
Ms. Rachel K. KingPres, CEO & Director834.9kN/A1959
Mr. Brian M. HahnSr. VP, CFO & Sec.524.45kN/A1974
Dr. John L. MagnaniSr. VP of Research & Chief Scientific Officer549.36kN/A1953
Dr. Helen M. ThackraySr. VP of Clinical Devel. & Chief Medical Officer593.23kN/A1968
Mr. Henry FlannerVP of Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

Corporate Governance

GlycoMimetics, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.